Achieve Life Sciences (ACHV) Total Liabilities (2010 - 2026)

Achieve Life Sciences has disclosed Total Liabilities across 17 years of filings, most recently posting $22.4 million for Q1 2026.

• Quarterly Total Liabilities rose 31.31% year-over-year to $22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.4 million (up 31.31% YoY) and the FY2025 annual result came in at $20.3 million, up 14.31% from the prior year.
• Total Liabilities improved to $22.4 million in Q1 2026, from $20.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $22.7 million in Q3 2022 and troughed at $16.5 million in Q3 2024.
• A 5-year average of $19.9 million and a median of $20.3 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 631.82% — and 2025, when it dropped 23.28%.
• Tracing ACHV's Total Liabilities over 5 years: stood at $21.7 million in 2022, then dropped by 3.92% to $20.8 million in 2023, then declined by 14.82% to $17.7 million in 2024, then advanced by 14.31% to $20.3 million in 2025, then increased by 10.63% to $22.4 million in 2026.
• Business Quant data shows ACHV's Total Liabilities at $22.4 million in Q1 2026, $20.3 million in Q4 2025, and $18.4 million in Q3 2025.